Morgan Stanley upgraded Medacta Group (MEDGF) to Overweight from Equal Weight with a CHF 135 price target The firm also upgrade the medical technology sector view to Attractive from In-line. Despite ongoing uncertainty into 2025, particularly around China, potential U.S. tariffs, inflation and consumer confidence,” we don’t think it is all doom and gloom for Medtech,” the analyst tells investors in a research note. Morgan Stanley expects some end market pressures will ease and says valuations screen well versus the broader European market and U.S. Medtech.